Investor
Relations
A+ / A-

Raporty

35/2013 Conclusion of a significant agreement

The annex to the agreement on mortgage for companies increases the value of the previously granted long-term credit by the amount of PLN 5.000.000. The total value of the credit amounts to PLN 9.600.000. The final date of repayment of the credit does not change with respect to the original agreement, i.e. 24 May 2017.

Increasing the amount of the long-term credit aims at partial replacement of the loans with higher interests and partial replacement of short-term financing with long-term financing.

Up to the amount of PLN 16.320.400, the credit is secured by a mortgage on the property located in Warszawa at Gilarska 86C, owned by Centrum Medyczne ENEL-MED S.A., including the assignment of rights resulting from the insurance agreement, unconfirmed assignment of receivables from the contracts concluded with the National Health Fund, and a civil code guarantee made by Centrum Medyczne Diagnostyka Sp. z o.o., subsidiary of the Issuer, which expires upon the sale of shares by the Borrower.

Other provisions of the agreement do not change.

The total value of all agreements concluded with Bank Millennium in the period of the last 12 months is PLN 29.600.000. The agreement of the highest value is the one concluded on 25 March 2013 on a multi-product line (including bank guarantees, sureties and LCs) for the amount of PLN 20.000.000 for the period from 25 March 2013 to 24 March 2014. The interest on the credit is a variable interest rate based on WIBOR 1M plus margin. The multi-product line is secured by a blank promissory note with a promissory note agreement, mortgage up to the amount of PLN 34.000.000 on the property of Centrum Medyczne ENEL-MED S.A. located in Warszawa at ul. Gilarska 86C, with the assignment of rights resulting from the insurance agreement and assignment of receivables from contracts.

The terms of the agreements do not differ from market conditions.

Those agreements are considered significant since their value exceeds 10% of the Issuer’s equity.